The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population-Reference-Cited by-同舟云学术

The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population

Published:2022-01-10 Issue:1 Volume:25 Page:87-98
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Kadakia Aditi¹,Brady Brenna L.²,Dembek Carole¹,Williams G. Rhys¹,Kent Justine M.¹

Affiliation:

1. Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

2. IBM Watson Health, Cambridge, MA, USA

Funder

Sunovion

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.2019501

Reference26 articles.

1. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

3. The Economic Burden of Schizophrenia in the United States in 2013

4. Health Insurance Coverage Among Persons With Schizophrenia in the United States

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation;Community Mental Health Journal;2024-09-06

2. Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis;BMJ Open;2024-09

3. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps;Journal of Managed Care & Specialty Pharmacy;2024-02-03

4. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication;Administration and Policy in Mental Health and Mental Health Services Research;2023-12-10

5. Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries;Journal of Medical Economics;2022-12-25